Celgene Lays Out Catalysts For Strong 2013, Highlights Apremilast
This article was originally published in The Pink Sheet Daily
Celgene reported strong sales for key products, led by Revlimid, during its year-end 2012 call. The biopharma affirmed 2013 guidance, detailing the key regulatory and commercial drivers that will power the global expansion of its hematology, oncology, and immunology franchises. In particular, it highlighted the commercial potential for apremilast.